Comparative Study on the Efficacy and Exposure of Molecular Target Agents in Non–small Cell Lung Cancer PDX Models with Driver Genetic Alterations

Scientists selected five NSCLC patient-derived xenografts (PDXs) with genetic alterations from established PDXs and the corresponding molecular targeted therapy was administered orally for 21 consecutive days.
[Molecular Cancer therapeutics]
[zotpress userid=’7992332′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Human Embryonic Mesenchymal Lung-Conditioned Medium Promotes Differentiation to Myofibroblast and Loss of Stemness Phenotype in Lung Adenocarcinoma Cell Lines

The authors reported that stimuli from the embryonic lung could modulate the malignant phenotype of lung cancer cells, control their growth capacity and activate their differentiation into myofibroblasts.
[Journal of Experimental & Clinical Cancer Research]
[zotpress userid=’7992332′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Development and Validation of a Hypoxia-Associated Signature for Lung Adenocarcinoma

Researchers developed a lung adenocarcinoma (LUAD) hypoxia-related gene expression signature. RNAseq was used to identify genes significantly differentially expressed under hypoxia in four LUAD cell lines.
[Scientific Reports]
[zotpress userid=’7992332′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Lyell Immunopharma Announces FDA Clearance of IND for LYL132, a T-cell Receptor Therapy for Solid Tumors Being Developed in Collaboration with GSK

Lyell Immunopharma, Inc. announced that the US FDA has cleared an Investigational New Drug (IND) application to initiate a Phase I clinical trial for LYL132, an investigational T-cell receptor therapy for patients with solid tumors expressing New York esophageal squamous cell carcinoma 1 that the company is developing in collaboration with GSK.
[Lyell Immunopharma, Inc.]
[zotpress userid=’7992332′ items=’BBBBBBBB’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Targeting ADRB2 Enhances Sensitivity of Non-Small Cell Lung Cancer to VEGFR2 Tyrosine Kinase Inhibitors

Investigators suggested that treatment with vascular endothelial growth factor receptor 2 (VEGFR2)-tyrosine kinase inhibitors upregulated ADRB2 expression in NSCLC cells.
[Cell Death Discovery]
[zotpress userid=’7992332′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Estrogen Receptor Beta Promotes Lung Cancer Invasion via Increasing CXCR4 Expression

Scientists found that ERβ could promote NSCLC cell invasion via increasing the circular RNA (circRNA), circ-TMX4, expression via directly binding to the 5′ promoter region of its host gene TMX4.
[Cell Death & Disease]
[zotpress userid=” items=’SPXSDFJC’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

RBL2/DREAM-Mediated Repression of the Aurora Kinase A/B Pathway Determines Therapy Responsiveness and Outcome in p53 WT NSCLC

Researchers found heightened expression of RB-family (RBL) 2 and reduced expression of AURKA/B pathway genes was associated with improved outcomes in p53 wild-type but not p53 mutant NSCLC patients.
[Scientific Reports]
[zotpress userid=” items=’SPXSDFJC’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Role of CTLA Inhibition in Management of Non-Small Cell Lung Cancer

The authors review the current role for CTLA-4 inhibitors in early-stage resectable NSCLC, unresectable stage III NSCLC, and in metastatic NSCLC.
[Current Oncology Reports]
[zotpress userid=” items=’SPXSDFJC’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Turning Point Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for Combination of Elzovantinib and Aumolertinib in EGFR Mutant Met-Amplified Non-small Cell Lung Cancer

Turning Point Therapeutics, Inc. announced that the company has received clearance from the FDA for the company’s Investigational New Drug application for the combination of elzovantinib and aumolertinib in EGFR mutant MET-amplified advanced non-small cell lung cancer.
[Turning Point Therapeutics]
[zotpress userid=” items=’SPXSDFJC’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Extracellular Vesicles Released by Non-Small Cell Lung Cancer Cells Drive Invasion and Permeability in Non-tumorigenic Lung Epithelial Cells

Secretion analysis revealed that cancer cells vary in their secretion level, with some cell lines having relatively low secretion rates.
[Scientific Reports]
[zotpress userid=” items=’SPXSDFJC’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

JMJD2C-Mediated Long Non-Coding RNA MALAT1/MicroRNA-503-5p/SEPT2 Axis Worsens Non-Small Cell Lung Cancer

Researchers explored the downstream mechanism of Jumonji domain containing protein 2C (JMJD2C) in NSCLC from the long non-coding RNA metastasis associated with lung adenocarcinoma transcript 1/microRNA-503-5p/septin 2 axis.
[Cell Death & Disease]
[zotpress userid=” items=’SPXSDFJC’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share
Share